Key result
Mechanistic and genetic evidence supports Lp(a) as a causal risk factor for ASCVD and CAVD.
Why the study?
Limited therapies currently exist for managing cardiovascular risk associated with elevated Lp(a), while several targeted therapies are in clinical development.
Answers are grounded in this paper and cite their sources.
This review summarizes the evidence supporting Lipoprotein(a) as a causal risk factor for cardiovascular disease and aortic stenosis, highlighting the need for and development of targeted therapies.
Lipoprotein(a) (Lp(a)) is an established risk factor for multiple cardiovascular diseases. Several lines of evidence including mechanistic, epidemiologic, and genetic studies support the role of Lp(a) as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis/calcific aortic valve disease (AS/CAVD). Limited therapies currently exist for the management of risk associated with elevated Lp(a), but several targeted therapies are currently in various stages of clinical development. In this review, we detail evidence supporting Lp(a) as a causal risk factor for ASCVD and AS/CAVD, and discuss approaches to managing Lp(a)-associated risk.
No takes yet. Share an insight, caveat, or question.
Bhatia et al. (2022) conducted a review in Atherosclerotic cardiovascular disease and aortic stenosis/calcific aortic valve disease. Lipoprotein(a) targeted therapies was evaluated. Lipoprotein(a) is supported by mechanistic, epidemiologic, and genetic evidence as a causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease.
Synapse has enriched 10 related papers. Consider them for comparative context: